Aptevo Therapeutics (NASDAQ: APVO) — Perfil da empresa, notícias e dados financeiros
Aptevo Therapeutics develops innovative oncology therapies with a focus on targeted treatments for unmet medical needs.

Aptevo Therapeutics
Aptevo Therapeutics (NASDAQ:APVO) is a biotechnology company focused on developing novel oncology and hematology treatments. They are driven by innovation in the field of protein engineering to create therapies that aim to improve patients' lives. Aptevo’s operations span from early-stage discovery and development to the clinical trial phase, with a strategic emphasis on targeted therapies that address unmet medical needs. Among its projects, the company is known for pioneering platforms that enable the generation of therapeutic candidates with improved pharmacological properties. A key objective for Aptevo is to advance its pipeline of innovative candidates through the development stages efficiently, aiming to bring breakthrough treatments to the market. Their work exemplifies a commitment to leveraging scientific insights for the development of life-saving and life-altering therapies.
Resumo
Operações
Produtos e/ou serviços de Aptevo Therapeutics
- APVO436: A bispecific antibody targeting CD123 and CD3 for acute myeloid leukemia and myelodysplastic syndrome.
- APVO603: A dual agonist bispecific antibody to costimulate T cells for cancer treatment.
- APVO210: A bispecific antibody designed to modulate the costimulatory signal for autoimmune diseases.
- ALG.APV-527: A bispecific antibody targeting 4-1BB and 5T4 antigens for solid tumors.
- RAPA-201-301: A Phase 1/2 trial for APVO436 in acute myeloid leukemia and high-grade myelodysplastic syndrome.
- XmAb®14045: A collaboration on an XmAb bispecific antibody for CD123-positive hematologic malignancies.
equipe executiva do Aptevo Therapeutics
- Marvin L. WhiteExecutive Chair
- Jeffrey G. LamotheCEO, President & Director
- SoYoung KwonCorporate Secretary, Senior VP, General Counsel, Business Development & Corporate Affairs
- Daphne L. TaylorSenior VP & CFO
- Mary J. JanatpourSenior VP & Chief Scientific Officer
- Miriam Weber MillerVice President of Investor Relations & Corporate Communications
- Dirk HuebnerSenior Vice President & Chief Medical Officer
Últimas notícias sobre a Aptevo Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Aptevo Therapeutics, em USD.
- Cap. de mercado
- 2,3 mi
- Receita (TTM)
- 0
- P/L
- 0.0
- LPA (diluído, TTM)
- 67.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -26,3 mi | -26 mi | |
| 0 | -24,6 mi | -24,1 mi | |
| 0 | -28,9 mi | -17,4 mi | |
| 3,1 mi | -28,6 mi | 8 mi |